Company intelligence / Profile preview
IACTA Pharmaceuticals
Guaynabo, Puerto Rico, United Statesiactapharma.com ↗
- Ownership
- Private
- Development stage
- Preclinical
01
Overview
IACTA has multiple products in development, with IC-265 having reached Phase 2 for dry eye syndrome, IC-270 in preclinical stage for allergic conjunctivitis, and IC-800 in preclinical development for ocular pain with $1 million funding from the U.S. Department of Defense.
- Therapeutic areas
- ImmunologyOphthalmology
- Modalities
- Small moleculesDual ENKephalinase Inhibitors (DENKI)SYK Kinase Inhibitors
- Industry
- Biotech
02
Drug pipeline
5 assets4 more assets in the full pipeline.
03
Partnerships
TALLC CorporationPharmaleadsOphthalmology Pharmaceutical (for Asian markets)
Beyond the preview
Go deeper on IACTA Pharmaceuticals.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on IACTA Pharmaceuticals.